Depression / MDD — Deal Benchmarks & Valuation
Market Analysis
Depression / MDD is one of the most actively transacted indications in neurology licensing. Phase 2 deals for depression / mdd carry a median total deal value of $2.6B, with upfront payments ranging from $144M to $439M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for depression / mdd deals allocate $753M to development milestones, $821M to regulatory milestones, and $707M to commercial milestones. Royalty rates range from 11.8% to 18.8% at the base tier, with tiered escalation reaching 15.8%-22.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for depression / mdd licensing?
What royalty rates are standard for depression / mdd deals?
How are depression / mdd deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.